guest ::
| Home > Publications database > Quality of life following total neoadjuvant therapy for rectal cancer. > print |
| Home > Publications database > Quality of life following total neoadjuvant therapy for rectal cancer. > print |
| 001 | 305535 | ||
| 005 | 20251028115603.0 | ||
| 024 | 7 | _ | |a 10.1007/s00432-025-06347-y |2 doi |
| 024 | 7 | _ | |a pmid:41137944 |2 pmid |
| 024 | 7 | _ | |a 0301-1585 |2 ISSN |
| 024 | 7 | _ | |a 0084-5353 |2 ISSN |
| 024 | 7 | _ | |a 0171-5216 |2 ISSN |
| 024 | 7 | _ | |a 1432-1335 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-02209 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Wurschi, Georg W |0 0000-0002-8751-9862 |b 0 |
| 245 | _ | _ | |a Quality of life following total neoadjuvant therapy for rectal cancer. |
| 260 | _ | _ | |a Heidelberg |c 2025 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1761574226_3448744 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a This study aimed to assess the health-related quality of life (HRQoL) in patients with locally advanced rectal cancer (LARC) undergoing total neoadjuvant therapy (TNT), comparing outcomes with the German general population and colorectal cancer (CRC) patients treated with curative intent.In a multicenter, cross-sectional study within the 'TNTox' study framework (DRKS 00033000), EORTC QLQ-C30 and QLQ-CR29 questionnaires were distributed to LARC patients who had completed TNT. Mean reference values were compared descriptively, and further exploratory comparisons based on clinical features were performed.The study included responses from 72 patients. Compared to the German general population, a reduction in mean HRQoL across most domains was observed; the strongest effect was observed for role functioning (- 28.7 points, Cohen's d = - 0.95), social functioning (- 25.3 points, d = - 0.89), and for diarrhea (+ 9.9 points, d = 0.80). General HRQoL was similar to that of CRC patients following curative treatment. However, some symptom scores, notably fecal incontinence (+ 13.4 points, d = 0.52), impotence (+ 29.0 points, d = 0.73), and dyspareunia (+ 10.4 points, d = 0.40) appeared to be higher. Significant factors associated with HRQoL included the presence of chronic treatment-related toxicity and duration of TNT; no major differences were observed between patients with or without NOM or stoma.LARC patients undergoing TNT showed comparable HRQoL outcomes to CRC patients treated with curative intent, but with reductions when compared to the general population. The presence of chronic toxicity significantly impacts HRQoL. Survivors may experience HRQoL impairments post-TNT, underscoring the necessity for ongoing management of chronic toxicity tailored to their needs. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a HRQoL |2 Other |
| 650 | _ | 7 | |a Organ preservation |2 Other |
| 650 | _ | 7 | |a QLQ-C30 |2 Other |
| 650 | _ | 7 | |a QLQ-CR29 |2 Other |
| 650 | _ | 7 | |a Quality of life |2 Other |
| 650 | _ | 7 | |a Rectal cancer |2 Other |
| 650 | _ | 7 | |a Total neoadjuvant therapy |2 Other |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Quality of Life |2 MeSH |
| 650 | _ | 2 | |a Rectal Neoplasms: therapy |2 MeSH |
| 650 | _ | 2 | |a Rectal Neoplasms: psychology |2 MeSH |
| 650 | _ | 2 | |a Rectal Neoplasms: pathology |2 MeSH |
| 650 | _ | 2 | |a Neoadjuvant Therapy: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Cross-Sectional Studies |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Surveys and Questionnaires |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Aged, 80 and over |2 MeSH |
| 700 | 1 | _ | |a Diefenhardt, Markus |0 0000-0002-9042-9729 |b 1 |
| 700 | 1 | _ | |a Kaufmann, Justus |0 0000-0003-0189-3499 |b 2 |
| 700 | 1 | _ | |a Ha, Hai Minh |b 3 |
| 700 | 1 | _ | |a Schneider, Melanie |b 4 |
| 700 | 1 | _ | |a von Ohlen, Daphne Schepers |b 5 |
| 700 | 1 | _ | |a Schöneich, Maren |b 6 |
| 700 | 1 | _ | |a Cieslak, Adrianna |0 0000-0001-7793-5494 |b 7 |
| 700 | 1 | _ | |a Depardon, Alina |b 8 |
| 700 | 1 | _ | |a Becker, Jan-Niklas |0 0000-0001-6972-0899 |b 9 |
| 700 | 1 | _ | |a Rühle, Alexander |0 P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9 |b 10 |u dkfz |
| 700 | 1 | _ | |a Ehret, Felix |0 0000-0001-6177-1755 |b 11 |
| 700 | 1 | _ | |a Römer, Maximilian |0 0000-0002-7069-4699 |b 12 |
| 700 | 1 | _ | |a Rißner, Florian |b 13 |
| 700 | 1 | _ | |a Hinz, Andreas |0 0000-0002-6986-8145 |b 14 |
| 700 | 1 | _ | |a Pietschmann, Klaus |b 15 |
| 773 | _ | _ | |a 10.1007/s00432-025-06347-y |g Vol. 151, no. 12, p. 304 |0 PERI:(DE-600)1459285-X |n 12 |p 304 |t Journal of cancer research and clinical oncology |v 151 |y 2025 |x 0301-1585 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:305535 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 0000-0001-6177-1755 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-20 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-20 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-20 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-20 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-20 |
| 920 | 1 | _ | |0 I:(DE-He78)FR01-20160331 |k FR01 |l DKTK Koordinierungsstelle Freiburg |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)BE01-20160331 |k BE01 |l DKTK Koordinierungsstelle Berlin |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)FR01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)BE01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|